Ozempic and Wegovy factory in North Carolina FAILS FDA inspection - sending ... trends now
An Ozempic and Wegovy factory in North Carolina that helps serve millions of Americans has failed an inspection, reports suggest.
The factory was found to have 'objectionable' conditions by the Food and Drug Administration (FDA).
Based in Clayton, North Carolina, the drug manufacturer now has three weeks to devise an action plan to rectify the issues or risk facing further action. Novo Nordisk, which owns the factory, says manufacturing is 'ongoing'.
The Danish company behind the blockbuster weight-loss drugs Ozempic and Wegovy has been rapidly expanding its manufacturing capacity to meet soaring demand — with five million prescriptions for its weight loss medications written in the US last year alone.
This surge led to major shortages of the drugs earlier this year, prompting pharmacies to mix their own versions.
Novo Nordisk now has three weeks to devise an action plan to rectify the issues or risk facing further action. Pictured above is its manufacturing plant
The share price for Novo Nordisk was down nearly three percent Monday, before rallying to $187.63 per share
The report, from financial news agency Market Wire News citing sources, said the factory was given a Form 483.
This is given to companies when inspectors from the FDA's Office of Regulatory Affairs observe conditions in manufacturing facilities they deem to be 'objectionable.'
The reason Novo Nordisk was issued the form has not been made public, but some objectionable conditions listed on Form 483 include dirty or damaged equipment, failure to properly store medications or insufficient paperwork.
The FDA inspectors are thought to have visited as part of a routine inspection, which the agency does to ensure factories are adhering to its standards.
When the report was revealed, the company's share price dropped
